Literature DB >> 30616002

ST-segment elevation and the Tpeak-Tend/QT ratio predict the occurrence of malignant arrhythmia events in patients with vasospastic angina.

Xianpei Wang1, Lu Zhang1, Chuanyu Gao2, Sha Wu1, Jialu Zhu1.   

Abstract

BACKGROUND: ST-segment elevation (STE) and an increased Tpeak-Tend interval (Tp-e) have prognostic value for malignant arrhythmia events (MAEs) in patients with ST-segment elevation myocardial infarction (STEMI) and Brugada syndrome. Whether STE could predict MAEs and has an electrophysiological relationship with Tp-e in electrocardiogram (ECG) of vasospastic angina (VA) patients needs to be elucidated.
METHODS: Sixty-five patients with VA and 23 patients with VA complicated by MAEs were enrolled. The relationship of ECG parameters and MAEs (defined as ventricular tachycardia/ventricular fibrillation (VT/VF), syncope, and aborted sudden death) was analyzed by t-test, regression and receiver operating characteristic (ROC) curve analyses.
RESULTS: Patients with MAEs showed greater STE (P<0.001) and corrected QT dispersion (cQTd) (P=0.021), a longer corrected Tp-e interval (cTp-e) (P<0.001), and a larger Tp-e/QT ratio (P<0.001) than those in non-MAE groups. Univariate analysis revealed that cQTd (odds ratio (OR)=1.065; P=0.020), cTp-e (OR=1.159; P=0.001), Tp-e/QT (OR=1.344, P=0.002), and STE (OR=5.655, P<0.001) were significantly associated with MAEs. In the multivariate analysis, Tp-e/QT and STE remained predictors of MAEs. ROC curve analysis showed that the areas under curve (AUCs) for Tp-e/QT (AUC=0.944) and STE (AUC=0.974) were not significantly different (P>0.05), but both were significantly different than AUCs for cQTd (AUC=0.724) and cTp-e (AUC=0.841) (all P<0.05). STE was well fitted with the Tp-e/QT ratio in a multivariable linear regression model.
CONCLUSIONS: STE and increased Tp-e/QT ratio had related electrophysiological properties and were independent prognostic indicators of MAEs in patients with VA.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  Malignant arrhythmia events; ST segment elevation; Tp-e interval; Tp-e/QT ratio; Vasospastic angina

Year:  2019        PMID: 30616002     DOI: 10.1016/j.jelectrocard.2019.01.001

Source DB:  PubMed          Journal:  J Electrocardiol        ISSN: 0022-0736            Impact factor:   1.438


  6 in total

1.  Variation of the T-wave peak-end interval and heart rate variability values in healthy males and females at various hours of the same day, and relationship of them.

Authors:  Ayhan Cosgun; Huseyin Oren
Journal:  J Arrhythm       Date:  2020-01-08

2.  The relationship between systolic pulmonary arterial pressure and Tp-e interval, Tp-e/QT, and Tp-e/QTc ratios in patients with newly diagnosed chronic obstructive pulmonary disease.

Authors:  Ayhan Cosgun; Huseyin Oren; Mustafa Hamidullah Turkkani
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-09-11       Impact factor: 1.468

3.  Variation of Tpeak-end, corrected Tpeak-end, QT, and corrected QT intervals, Tpeak-end/QT, Tpeak-end/corrected QT ratios and heart rate variability according to decades in the healthy male subjects aged between 30 and 79 years.

Authors:  Ayhan Cosgun; Huseyin Oren
Journal:  J Arrhythm       Date:  2020-04-13

4.  Effect of ranolazine on Tp-e interval, Tp-e/QTc, and P-wave dispersion in patients with stable coronary artery disease.

Authors:  Murat Akcay; Metin Coksevim; Mustafa Yenercag
Journal:  J Arrhythm       Date:  2021-05-17

5.  Development and Validation of a Risk Prediction Model for Ventricular Arrhythmia in Elderly Patients with Coronary Heart Disease.

Authors:  Ying Dong; Yajun Shi; Jinli Wang; Qing Dan; Ling Gao; Chenghui Zhao; Yang Mu; Miao Liu; Chengliang Yin; Rilige Wu; Yuqi Liu; Yang Li; Xueping Wang
Journal:  Cardiol Res Pract       Date:  2021-07-02       Impact factor: 1.866

Review 6.  Handling of Ventricular Fibrillation in the Emergency Setting.

Authors:  Zoltán Szabó; Dóra Ujvárosy; Tamás Ötvös; Veronika Sebestyén; Péter P Nánási
Journal:  Front Pharmacol       Date:  2020-01-29       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.